Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest TransCelerate BioPharma Inc. Stories

2014-02-25 08:33:10

PHILADELPHIA, Feb. 25, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced the appointment of Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately. Dr. Jenkins, who previously served as a member of the Board of Directors, will work closely with TransCelerate CEO Dr. Dalvir Gill to...

2014-01-30 08:32:11

PHILADELPHIA, Jan. 30, 2014 /PRNewswire/ -- In its continued effort to modernize and streamline the way clinical trials are conducted and monitored, TransCelerate BioPharma Inc. ("TransCelerate") is providing the first update to its position paper outlining a methodology for risk-based site monitoring ("Risk-Based Monitoring" or "RBM") released in June 2013. The update is a result of continued refinement of the position paper's concepts and assessing the experiences and lessons...

2014-01-29 12:27:40

CFAST Develops Processes to Accelerate Understanding of Alzheimer's disease and Asthma AUSTIN, Texas, Jan. 29, 2014 /PRNewswire-USNewswire/ -- The Clinical Data Interchange Standards Consortium (CDISC), Critical Path Institute (C-Path) and TransCelerate BioPharma Inc. ("TransCelerate") announced today that version 1.0 of the Asthma Therapeutic Area (TA) User Guide (UG) and version 2.0 of the Alzheimer's TAUG are now available for implementers on the CDISC website. These user guides...

2013-11-07 08:34:03

PHILADELPHIA, Nov. 7, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") is launching three new global initiatives to further advance efficiency in clinical trials and accelerate the development of new medicines: creation of common clinical trial protocol templates, development of clinical trial networks for pediatric and minority populations, and establishment of a global investigator registry. TransCelerate is also expanding two of its original five initiatives, the...

2013-09-18 08:30:48

AUSTIN, Texas, Sept. 18, 2013 /PRNewswire/ -- The Clinical Data Interchange Standards Consortium (CDISC) and TransCelerate BioPharma Inc. ("TransCelerate"), are pleased to announce that version 1.0 of the Asthma Therapeutic Area (TA) Data Standard is now available for public review on the CDISC website. The Asthma TA standard is the first standard to have been developed with TransCelerate's active participation in the Coalition for Accelerating Standards and Therapies (CFAST)...

2013-08-06 08:35:39

PHILADELPHIA, Aug. 6, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has reached its primary milestone in its Clinical Trial Comparator Network ("Comparator Network") initiative. Formed to establish reliable, rapid sourcing of quality drug products for use in clinical trials, the Comparator Network will enable accelerated clinical trial timelines and enhanced patient safety. In July 2013, a master service agreement (MSA), affirming a mutual...

2013-06-20 23:03:58

The Clinical Data Interchange Standards Consortium (CDISC) announced plans today to implement CDISC SHARE. After a comprehensive proposal and evaluation process, SOA Software´s Semantic Manager product was chosen as the SHARE technology platform by a selection committee consisting of CDISC leaders and volunteers, with substantial support from TransCelerate BioPharma Inc. (TransCelerate). Austin, TX (PRWEB) June 20, 2013 The Clinical Data Interchange Standards Consortium (CDISC)...

2013-06-20 12:31:47

PHILADELPHIA, June 20, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has reached several important milestones in its initiative to realize efficiencies across clinical trial investigator and site qualification and training ("SQT") efforts. In order to address areas of discord voiced by investigators and sites, TransCelerate's sixteen biopharmaceutical company members are implementing the first three deliverables of the SQT initiative: a set of...

2013-06-03 08:29:25

PHILADELPHIA, June 3, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate"), an independent non-profit organization focused on accelerating the development of new medicines, today released a position paper outlining a methodology for risk-based site monitoring ("Risk-Based Monitoring" or "RBM") that could significantly modernize and streamline the way studies are conducted and monitored. The RBM position paper reflects TransCelerate's collaborative approach to improve speed,...

2013-04-15 08:30:29

PHILADELPHIA, April 15, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that six new pharmaceutical companies have joined as members of the independent non-profit entity formed to assess, refine and create processes to bring innovative new medicines to the public faster. The addition of the new members to TransCelerate marks a major milestone since the organization's founding by ten healthcare and pharmaceutical companies in September 2012. The new member...